Results 111 to 120 of about 54,210 (294)

Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.
Abstract Aims We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.
Valérie Olié   +5 more
wiley   +1 more source

A phenomap of TTR amyloidosis to aid diagnostic screening

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1113-1118, April 2025.
Abstract Cardiac amyloidosis due to transthyretin (ATTR) remains an underdiagnosed cause of cardiomyopathy. As awareness of the disease grows and referrals for ATTR increase, clinicians are likely to encounter more atypical forms of the condition in clinical practice.
Alexios S. Antonopoulos   +4 more
wiley   +1 more source

Current therapies for AL amyloidosis: literature review and our data

open access: yesКлиническая онкогематология, 2013
AL amyloidosis is a relatively rare condition belonging to plasma cell dyscrasias with very heterogeneous clinical presentation and poor prognosis. This article presents a brief description of AL amyloidosis, current therapies, and our own statistics on ...
A. G. Smirnova   +5 more
doaj   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer   +25 more
wiley   +1 more source

Therapeutic options in systemic AL amyloidosis

open access: yes, 2004
Systemic amyloid light chain (AL) amyloidosis is a severe disease with unfavourable prognosis. Since the late 1970s different therapeutic modalities in AL amyloidosis have been investigated, trying to prolong survival.
Vellenga, E   +3 more
core   +1 more source

Nutritional Status of Outpatients with Al Systemic Amyloidosis

open access: yes, 2004
This volume contains 179 chapters by international experts on recent developments in our understanding of amyloid proteins, protein folding disorders, and new and proposed clinical trials in amyloidosis.
Vagia, C   +5 more
core   +1 more source

Localized AL amyloidosis: A suicidal neoplasm?

open access: yes, 2012
Although AL amyloidosis usually is a systemic disease, strictly localized AL deposits are not exceptionally rare. Such case reports form a considerable body of published articles.
Per Westermark, Westermark, Per,
core   +1 more source

Amyloidosis AL. Case study

open access: yes, 2017
Amyloidozy to heterogenna grupa chorób, których istotą jest odkładanie się nierozpuszczalnych włókienek białkowych w tkankach i narządach, prowadzące do ich stopniowej dysfunkcji.
Major-Gołuch, Agnieszka   +2 more
core  

Chemistry Underlying the Behavior of Food and Agricultural Components During Industrial Manufacturing Processes and Its Implications in Quality Assurance, Food Quality, and Food Safety Management: A Systematic Review

open access: yesFood Safety and Health, EarlyView.
Industrial manufacturing processes have transformative effects on the components of food matrix. These transformations in food matrix and components have direct implications for quality assurance (QA), food quality (e.g., nutritional profile and texture), and food safety management (e.g., pathogen control and toxin mitigation). ABSTRACT This systematic
Chinaza Godswill Awuchi
wiley   +1 more source

BCMA CAR T for AL Amyloidosis After Plasmacytic Relapse of Lymphoplasmacytic Lymphoma. [PDF]

open access: yesEJHaem
ABSTRACT Introduction Lambda immunoglobulin light chain (AL) amyloidosis associated with non‐IgM lymphoplasmacytic lymphoma (LPL) is rare and often refractory to conventional therapies. Treatment options for relapsed disease remain limited. Methods Here we describe the case of a patient with a history of LPL‐associated AL amyloidosis who had previously
Al Haddad N   +5 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy